European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Basel, 14 March 2019 European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given subcutaneously and with multiple dosing options The efficacy and safety of... Read more